Stock Scorecard



Stock Summary for Axsome Therapeutics Inc (AXSM) - $95.50 as of 11/20/2024 7:47:40 PM EST

Total Score

3 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AXSM

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AXSM

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AXSM

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AXSM

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AXSM (44 out of 90)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for AXSM

Is It Too Late to Buy Viking Therapeutics Stock? 11/17/2024 12:05:00 PM
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up 11/13/2024 4:08:00 PM
Axsome Therapeutics ( AXSM ) Q3 2024 Earnings Call Transcript 11/12/2024 8:15:00 PM
Axsome Therapeutics ( AXSM ) Reports Q3 Loss, Tops Revenue Estimates 11/12/2024 1:15:00 PM
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts? 11/11/2024 3:46:00 PM
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - Axsome Therapeutics ( NASDAQ:AXSM ) 11/8/2024 12:00:00 PM
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 11/8/2024 12:00:00 PM
Tarsus Pharmaceuticals, Inc. ( TARS ) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 11/7/2024 3:00:00 PM
Analysts Estimate Axsome Therapeutics ( AXSM ) to Report a Decline in Earnings: What to Look Out for 11/5/2024 3:00:00 PM
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 - Axsome Therapeutics ( NASDAQ:AXSM ) 10/29/2024 11:00:00 AM

Financial Details for AXSM

Company Overview

Ticker AXSM
Company Name Axsome Therapeutics Inc
Country USA
Description Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date 2/18/2025

Stock Price History

Last Day Price 95.50
Price 4 Years Ago 81.47
Last Day Price Updated 11/20/2024 7:47:40 PM EST
Last Day Volume 403,245
Average Daily Volume 497,021
52-Week High 105.00
52-Week Low 60.28
Last Price to 52 Week Low 58.43%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -18.62
Free Cash Flow Ratio 14.15
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 2.44
Total Cash Per Share 6.75
Book Value Per Share Most Recent Quarter 1.92
Price to Book Ratio 49.80
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 13.67
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 12
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 48,462,400
Market Capitalization 4,628,159,200
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -27.84%
Reported EPS 12 Trailing Months -6.58
Reported EPS Past Year -4.45
Reported EPS Prior Year -5.20
Net Income Twelve Trailing Months -310,955,000
Net Income Past Year -239,238,000
Net Income Prior Year -187,134,000
Quarterly Revenue Growth YOY 81.30%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -0.44

Balance Sheet

Total Cash Most Recent Quarter 327,341,000
Total Cash Past Year 386,193,000
Total Cash Prior Year 200,841,955
Net Cash Position Most Recent Quarter -28,967,000
Net Cash Position Past Year 30,733,000
Long Term Debt Past Year 355,460,000
Long Term Debt Prior Year 187,896,155
Total Debt Most Recent Quarter 356,308,000
Equity to Debt Ratio Past Year 0.35
Equity to Debt Ratio Most Recent Quarter 0.21
Total Stockholder Equity Past Year 190,977,000
Total Stockholder Equity Prior Year 109,556,000
Total Stockholder Equity Most Recent Quarter 92,898,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -132,817,000
Free Cash Flow Per Share Twelve Trailing Months -2.74
Free Cash Flow Past Year -145,662,000
Free Cash Flow Prior Year -117,213,109

Options

Put/Call Ratio 2.68
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.72
MACD Signal 1.06
20-Day Bollinger Lower Band 81.59
20-Day Bollinger Middle Band 88.95
20-Day Bollinger Upper Band 96.31
Beta 1.25
RSI 52.81
50-Day SMA 82.35
150-Day SMA 64.99
200-Day SMA 61.23

System

Modified 11/20/2024 6:42:10 PM EST